drugset
drugset / Trial / NCT00162097

Pharmacokinetics of Efavirenz in HIV-1 Infected Subjects With Hepatic Impairment

NCT00162097 ↗

Phase 1 Completed 21 enrolled Bristol-Myers Squibb
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study was to assess the steady-state pharmacokinetics (PK) of efavirenz (EFV) in human immunodeficiency virus type 1 (HIV-1) infected subjects on stable antiretroviral regimens containing EFV, and having selected degrees of hepatic impairment or normal hepatic function.

Timeline

Start
2004-11
Primary completion
2008-03
Completion
2008-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Efavirenz Other / unclassified 600 mg Oral

Indications

HIV infectious disease